Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine

Vaccine ◽  
2003 ◽  
Vol 21 (17-18) ◽  
pp. 2207-2217 ◽  
Author(s):  
K NICHOL
Keyword(s):  
Clinical Trial ◽  
Influenza Virus ◽  
Economic Analysis ◽  
Influenza Vaccination ◽  
Virus Vaccine ◽  
Cost Benefit ◽  
Influenza Virus Vaccine ◽  
Working Adults ◽  
Healthy Working ◽  
Live Attenuated Influenza Virus

Economic Analysis of Influenza Vaccination and Antiviral Treatment for Healthy Working Adults

2002 ◽  
Vol 137 (4) ◽  
pp. 225 ◽  
Author(s):  
Patrick Y. Lee ◽  
David B. Matchar ◽  
Dennis A. Clements ◽  
Joel Huber ◽  
John D. Hamilton ◽  
...  
Keyword(s):  
Economic Analysis ◽  
Influenza Vaccination ◽  
Antiviral Treatment ◽  
Working Adults ◽  
Healthy Working

scholarly journals Development of a Mouse-Adapted Live Attenuated Influenza Virus That PermitsIn VivoAnalysis of Enhancements to the Safety of Live Attenuated Influenza Virus Vaccine

2014 ◽  
Vol 89 (6) ◽  
pp. 3421-3426 ◽  
Author(s):  
Andrew Cox ◽  
Steven F. Baker ◽  
Aitor Nogales ◽  
Luis Martínez-Sobrido ◽  
Stephen Dewhurst
Keyword(s):  
Influenza Virus ◽  
Virus Vaccine ◽  
Safety Analysis ◽  
Influenza Virus Vaccine ◽  
Safety Concerns ◽  
High Doses ◽  
Live Attenuated Influenza Virus

The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pathogenicity that retains lethality at high doses and further demonstrate that we can enhance safetyin vivothrough mutations within NS1. This model may permit preliminary safety analysis of improved LAIVs.

scholarly journals Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial

2020 ◽  
Vol 20 (1) ◽  
pp. 80-91 ◽  
Author(s):  
David I Bernstein ◽  
Jeffrey Guptill ◽  
Abdollah Naficy ◽  
Raffael Nachbagauer ◽  
Francesco Berlanda-Scorza ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Influenza Virus ◽  
Virus Vaccine ◽  
Phase 1 ◽  
Influenza Virus Vaccine ◽  
Vaccine Candidates ◽  
Phase 1 Clinical Trial
Sign in / Sign up

Export Citation Format

Share Document